Daniel Wu, MD
Hematology-Oncology · Torrance, CANPI 1932519790
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AstraZeneca at 31.5% of the total. Reporting peaked in 2019 at $1,358 and has fallen 97.9% since, to $28 in 2021. That places this record below the midpoint for hematology-oncology clinicians in CA, where the typical reported total is $1,839.
Across 65 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$473
- E.r. Squibb & Sons, L.L.C.$231
- Lilly USA, LLC$184
- Genentech USA, Inc.$94
- Incyte Corporation$75
- Pharmacyclics LLC, An Abbvie Company$64
- plus $381 from 12 others
What the payments were for
- Food & beverage$1,40193%
- Education$1007%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 12 | $473 |
| E.r. Squibb & Sons, L.L.C. | 17 | $231 |
| Lilly USA, LLC | 6 | $184 |
| Genentech USA, Inc. | 5 | $94 |
| Incyte Corporation | 4 | $75 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $64 |
| Merck | 3 | $53 |
| Gilead(2 entities) | 2 | $50 |
| Pfizer | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Bristol Myers Squibb | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Amgen | 1 | $24 |
| Sanofi | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Seagen Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Exelixis Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,501 in reported general payments places this provider in the 45th percentile of 53 hematology-oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 65 | $880,077 |
| TagrissoOsimertinib Mesylate | 37 | $635,885 |
| XtandiEnzalutamide | 45 | $549,149 |
| BrukinsaZanubrutinib | 27 | $355,099 |
| InlytaAxitinib | 18 | $346,809 |
| LenvimaLenvatinib Mesylate | 14 | $294,688 |
| RetevmoSelpercatinib | 12 | $294,277 |
| LynparzaOlaparib | 14 | $226,766 |
| JakafiRuxolitinib Phosphate | 14 | $225,398 |
| SprycelDasatinib | 12 | $215,352 |
| KisqaliRibociclib Succinate | 16 | $177,759 |
| TykerbLapatinib Ditosylate | 12 | $77,934 |
| VenclextaVenetoclax | 13 | $46,989 |
| EliquisApixaban | 37 | $33,238 |
| NivestymFilgrastim-Aafi | 30 | $25,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Lynparza | $473 | $862,65151 claims |
| PfizerInlyta, Eliquis, Nivestym | $49 | $405,16285 claims |
| Lilly USA, LLCRetevmo | $184 | $294,27712 claims |
| Incyte CorporationJakafi | $75 | $225,39814 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $231 | $215,35212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 53 hematology-oncology providers in California.
Other hematology-oncology in Torrance
- James BerensonWest Hollywood$1M
- Ari BaronSan Francisco$705K
- Jeffrey WolfSan Francisco$407K
- Haresh JhangianiFountain Valley$77K
- Mark ScholzMarina del Rey$62K
- Derrick SuFountain Valley$53K
- Peyman Salimi-TariFountain Valley$49K
- Janet PanFountain Valley$46K
- Bertrand TuanSan Francisco$45K
- Brian ChoiRiverside$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.